Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Molecular residual disease (MRD) is a promising biomarker in colorectal cancer (CRC) for prognosis and guiding treatment, while the whole-exome sequencing (WES) based tumor-informed assay is standard for evaluating MRD based on circulating tumor DNA (ctDNA). In this study, we assessed the feasibility of a fixed-panel for evaluating MRD in CRC. Materials and Methods Seventy-five patients with resectable stage I-III CRC were enrolled. Tumor tissues obtained by surgery, and preoperative and postoperative day 7 blood samples were collected. The ctDNA was evaluated using the tumor-agnostic and tumor-informed fixed assays, as well as the WES-based and panel-based personalized assays in randomly selected patients. Results The tumor-informed fixed assay had a higher preoperative positive rate than the tumor-agnostic assay (73.3% vs. 57.3%). The preoperative ctDNA status failed to predict disease-free survival (DFS) in either of the fixed assays, while the tumor-informed fixed assay-determined postoperative ctDNA positivity was significantly associated with worse DFS (hazard ratio [HR], 20.74; 95% confidence interval [CI], 7.19 to 59.83; p < 0.001), which was an independent predictor by multivariable analysis (HR, 28.57; 95% CI, 7.10 to 114.9; p < 0.001). Sub-cohort analysis indicated the WES-based personalized assay had the highest preoperative positive rate (95.1%). The two personalized assays and the tumor-informed fixed assay demonstrated same results in postoperative landmark (HR, 26.34; 95% CI, 6.01 to 115.57; p < 0.001), outperforming the tumor-agnostic fixed panel (HR, 3.04; 95% CI, 0.94 to 9.89; p=0.052). Conclusion Our study confirmed the prognostic value of the ctDNA positivity at postoperative day 7 by the tumor-informed fixed panel. The tumor-informed fixed panel may be a cost-effective method to evaluate MRD, which warrants further studies in future.
Abstract
Purpose Molecular residual disease (MRD) is a promising biomarker in colorectal cancer (CRC) for prognosis and guiding treatment, while the whole-exome sequencing (WES) based tumor-informed assay is standard for evaluating MRD based on circulating tumor DNA (ctDNA). In this study, we assessed the feasibility of a fixed-panel for evaluating MRD in CRC. Materials and Methods Seventy-five patients with resectable stage I-III CRC were enrolled. Tumor tissues obtained by surgery, and preoperative and postoperative day 7 blood samples were collected. The ctDNA was evaluated using the tumor-agnostic and tumor-informed fixed assays, as well as the WES-based and panel-based personalized assays in randomly selected patients. Results The tumor-informed fixed assay had a higher preoperative positive rate than the tumor-agnostic assay (73.3% vs. 57.3%). The preoperative ctDNA status failed to predict disease-free survival (DFS) in either of the fixed assays, while the tumor-informed fixed assay-determined postoperative ctDNA positivity was significantly associated with worse DFS (hazard ratio [HR], 20.74; 95% confidence interval [CI], 7.19 to 59.83; p < 0.001), which was an independent predictor by multivariable analysis (HR, 28.57; 95% CI, 7.10 to 114.9; p < 0.001). Sub-cohort analysis indicated the WES-based personalized assay had the highest preoperative positive rate (95.1%). The two personalized assays and the tumor-informed fixed assay demonstrated same results in postoperative landmark (HR, 26.34; 95% CI, 6.01 to 115.57; p < 0.001), outperforming the tumor-agnostic fixed panel (HR, 3.04; 95% CI, 0.94 to 9.89; p=0.052). Conclusion Our study confirmed the prognostic value of the ctDNA positivity at postoperative day 7 by the tumor-informed fixed panel. The tumor-informed fixed panel may be a cost-effective method to evaluate MRD, which warrants further studies in future.
참고문헌 (28)
- Biller LH, "Diagnosis and treatment of metastatic colorectal cancer : a review", JAMA, 325, pp.669~685 (2021)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Figueredo A, "Adjuvant therapy for stage II colon cancer : a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group", J Clin Oncol, 22, pp.3395~3407 (2004)
- Andre T, "Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer : updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study", J Clin Oncol, 33, pp.4176~4187 (2015)
- Bockelman C, "Risk of recurrence in patients with colon cancer stage II and III : a systematic review and meta-analysis of recent literature", Acta Oncol, 54, pp.5~16 (2015)
- Quasar Collaborative Group, "Adjuvant chemotherapy versus observation in patients with colorectal cancer : a randomised study", Lancet, 370, pp.2020~2029 (2007)
- Dasari A, "ctDNA applications and integration in colorectal cancer : an NCI Colon and Rectal-Anal Task Forces whitepaper", Nat Rev Clin Oncol, 17, pp.757~770 (2020)
- Moding EJ, "Detecting liquid remnants of solid tumors : circulating tumor DNA minimal residual disease", Cancer Discov, 11, pp.2968~2986 (2021)
- Kotani D, "Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer", Nat Med, 29, pp.127~134 (2023)
- Tie J, "Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer", N Engl J Med, 386, pp.2261~2272 (2022)
- Chen K, "Commercial ctDNA assays for minimal residual disease detection of solid tumors", Mol Diagn Ther, 25, pp.757~774 (2021)
- Zhou J, "Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer : a prospective multicenter study", Clin Cancer Res, 27, pp.301~310 (2021)
- Reinert T, "Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer", JAMA Oncol, 5, pp.1124~1131 (2019)
- Zhu L, "A novel and reliable method to detect microsatellite instability in colorectal cancer by next-generation sequencing", J Mol Diagn, 20, pp.225~231 (2018)
- Chen K, "Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer", Cancer Cell, 41, pp.1749~1762 (2023)
- Ye ZL, "Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis", Cancer Med, 9, pp.745~756 (2020)
- Tie J, "Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases : a prospective cohort study", PLoS Med, 18, pp.e1003620~ (2021)
- Schraa SJ, "Cell-free circulating(tumor)DNA before surgery as a prognostic factor in non-metastatic colorectal cancer : a systematic review", Cancers(Basel), 14, pp.2218~ (2022)
- Li N, "Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer", Cancer, 128, pp.708~718 (2022)
- Gianni C, "Potential impact of preoperative circulating biomarkers on individual escalating", de-escalating strategies in early breast cancer, 2022, pp.15, 96~
- Tie J, "Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer", JAMA Oncol, 5, pp.1710~1717 (2019)
- Taieb J, "Analysis of circulating tumour DNA(ctDNA)from patients enrolled in the IDEA-FRANCE phase III trial : prognostic and predictive value for adjuvant treatment duration", Ann Oncol, 30(Suppl 5), pp.V867~ (2019)
- Geltzeiler CB, "Prospective study of colorectal enhanced recovery after surgery in a community hospital", JAMA Surg, 149, pp.955~961 (2014)
- "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer. Version 1.2024", National Comprehensive Cancer Network, ~ (2024)
- Chen G, "Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer", J Hematol Oncol, 14, pp.80~ (2021)
- Henriksen TV, "The effect of surgical trauma on circulating free DNA levels in cancer patients-imp-lications for studies of circulating tumor DNA", Mol Oncol, 14, pp.1670~1679 (2020)
- Frey P, "SMAD4 mutations do not preclude epithelial-mesenchymal transition in colorectal cancer", Oncogene, 41, pp.824~837 (2022)
- Mao X, "Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer", J Thorac Oncol, 12, pp.663~672 (2017)